Your browser doesn't support javascript.
loading
Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease.
Yang, Tao; Cui, Xue; Tang, Minghai; Qi, Wenyan; Zhu, Zejiang; Shi, Mingsong; Yang, Linyu; Pei, Heying; Zhang, Wanhua; Xie, Lixin; Xu, Yaohui; Yang, Zhuang; Chen, Lijuan.
Afiliação
  • Yang T; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu 610041, China.
  • Cui X; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu 610041, China.
  • Tang M; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu 610041, China.
  • Qi W; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu 610041, China.
  • Zhu Z; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu 610041, China.
  • Shi M; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu 610041, China.
  • Yang L; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu 610041, China.
  • Pei H; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu 610041, China.
  • Zhang W; Department of Hematology, West China Hospital of Sichuan University, Chengdu 610041, China.
  • Xie L; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu 610041, China.
  • Xu Y; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu 610041, China.
  • Yang Z; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu 610041, China.
  • Chen L; Chengdu Zenitar Biomedical Technology Co., Ltd., Chengdu 610041, China.
J Med Chem ; 65(4): 3151-3172, 2022 02 24.
Article em En | MEDLINE | ID: mdl-35113547
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais / Inibidores de Proteínas Quinases / Janus Quinase 1 / TYK2 Quinase Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Revista: J Med Chem Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais / Inibidores de Proteínas Quinases / Janus Quinase 1 / TYK2 Quinase Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Revista: J Med Chem Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China